TABRECTA is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Capmatinib.
| Product ID | 0078-0716_09072608-375f-4c64-b09a-8fc453868473 |
| NDC | 0078-0716 |
| Product Type | Human Prescription Drug |
| Proprietary Name | TABRECTA |
| Generic Name | Capmatinib |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2020-05-06 |
| Marketing Category | NDA / NDA |
| Application Number | NDA213591 |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | CAPMATINIB |
| Active Ingredient Strength | 200 mg/1 |
| Pharm Classes | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Kinase Inhibitor [EPC], Mesenchymal Epithelial Transition Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 2 K Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2020-05-06 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA213591 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2020-05-06 |
| Marketing Category | NDA |
| Application Number | NDA213591 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2020-05-06 |
| Ingredient | Strength |
|---|---|
| CAPMATINIB | 200 mg/1 |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0078-0709 | TABRECTA | capmatinib |
| 0078-0716 | TABRECTA | capmatinib |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() TABRECTA 79281021 not registered Live/Pending |
NOVARTIS AG 2020-01-22 |
![]() TABRECTA 79148570 4630489 Live/Registered |
NOVARTIS AG 2014-03-21 |